Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan

BACKGROUND: Infliximab, an anti-tumor necrosis factor-alpha antibody, has been reported to have excellent efficacy for refractory uveoretinitis in Behçet’s disease (RUBD), and was approved for this indication in Japan. However, the long-term safety profile and efficacy in real-world clinical setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohno, Shigeaki, Umebayashi, Itsuro, Matsukawa, Miyuki, Goto, Takashi, Yano, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321670/
https://www.ncbi.nlm.nih.gov/pubmed/30611312
http://dx.doi.org/10.1186/s13075-018-1793-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321670/
https://www.ncbi.nlm.nih.gov/pubmed/30611312
http://dx.doi.org/10.1186/s13075-018-1793-7

Ejemplares similares